局部进展期直肠癌新辅助放化疗后肿瘤退缩的影响因素分析及预测模型构建

刘志昱; 徐栋; 陈西昊; 李纪鹏

doi:10.19401/j.cnki.1007-3639.2024.02.007

您当前的位置：

首页 >

文章列表页 >

局部进展期直肠癌新辅助放化疗后肿瘤退缩的影响因素分析及预测模型构建

论著 | 更新时间：2025-12-31

- 局部进展期直肠癌新辅助放化疗后肿瘤退缩的影响因素分析及预测模型构建
- Influencing factors and establishment of a prediction model for the tumor regression after neoadjuvant chemoradiotherapy in locally advanced rectal cancer
- 中国癌症杂志 2024年34卷第2期页码：191-200
- 作者机构：
  
  1. 西安医学院研究生处，陕西西安 710068
  2. 空军军医大学第一附属医院消化外科，陕西西安 710032
- 作者简介：
  
  [ "刘志昱（ORCID: 0009-0006-4386-2534），硕士，住院医师。" ]
  李纪鹏（ORCID: 0000-0001-8822-1518），博士，主任医师、教授、博士研究生导师，空军军医大学第一附属医院消化外科副主任。
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2024.02.007
  中图分类号： R735.3+7
- 收稿：2023-03-15，
  
  修回：2023-12-15，
  
  纸质出版：2024-02-29
- 稿件说明：
移动端阅览
刘志昱, 徐栋, 陈西昊, 等. 局部进展期直肠癌新辅助放化疗后肿瘤退缩的影响因素分析及预测模型构建[J]. 中国癌症杂志, 2024,34(2):191-200.

Zhiyu LIU, Dong XU, Xihao CHEN, et al. Influencing factors and establishment of a prediction model for the tumor regression after neoadjuvant chemoradiotherapy in locally advanced rectal cancer[J]. China Oncology, 2024, 34(2): 191-200.
刘志昱, 徐栋, 陈西昊, 等. 局部进展期直肠癌新辅助放化疗后肿瘤退缩的影响因素分析及预测模型构建[J]. 中国癌症杂志, 2024,34(2):191-200. DOI： 10.19401/j.cnki.1007-3639.2024.02.007.

Zhiyu LIU, Dong XU, Xihao CHEN, et al. Influencing factors and establishment of a prediction model for the tumor regression after neoadjuvant chemoradiotherapy in locally advanced rectal cancer[J]. China Oncology, 2024, 34(2): 191-200. DOI： 10.19401/j.cnki.1007-3639.2024.02.007.

摘要

背景与目的：

局部进展期直肠癌（locally advanced rectal cancer，LARC）的标准治疗策略是新辅助放化疗（neoadjuvant chemoradiotherapy，nCRT）后进行手术治疗，nCRT可以使肿块缩小，实现肿瘤降期，增加R0切除率。但直肠癌个体差异较大，有部分患者对nCRT反应较差，并不能从nCRT中获益。因此，采取有效的筛选措施，以识别nCRT效果不佳的患者很有必要。本研究旨在探讨临床基线指标对LARC nCRT后肿瘤退缩的预测价值并构建肿瘤退缩预测模型。

方法：

收集2016年1月—2020年12月在空军军医大学第一附属医院接受nCRT治疗且行全直肠系膜切除术的LARC患者，收集入组患者nCRT前的临床基线指标，包括实验室检查、肿瘤标志物和磁共振成像（magnetic resonance imaging，MRI）资料。根据nCRT前后的MRI报告的肿瘤大小，通过实体瘤疗效评价标准（Response Evaluation Criteria in Solid Tumors，RECIST）来评价LARC患者nCRT后肿瘤退缩程度。使用受试者工作特征（receiver operating characteristic，ROC）曲线对临床基线指标标准化处理后，进行多因素分析，筛选影响肿瘤退缩的因素，通过logistic回归构建肿瘤退缩预测模型，采用决策曲线分析（decision curve analysis，DCA）和校准曲线对模型的预测性能进行评估，并通过十折交叉验证来检测模型的准确度。

结果：

本回顾性队列研究共入组158例患者，其中98例患者nCRT后肿瘤退缩良好，达到完全缓解（complete response，CR）或部分缓解（partial response，PR），客观缓解率为62%；60例患者退缩不良，为疾病稳定（stable disease，SD）或疾病进展（progressive disease，PD）。多因素分析表明，治疗前肿瘤直径（

0.001）、nCRT后距离手术的时间（

= 0.006）、D-二聚体（

= 0.010）、预后营养指数（prognostic nutrition index，PNI）（

= 0.035）、癌胚抗原（carcinoembryonic antigen，CEA）（

= 0.004）、壁外血管侵犯（extramural vascular invasion，EMVI）（

= 0.026）与nCRT后肿瘤退缩显著相关。LARC nCRT后肿瘤退缩预测模型的ROC曲线的曲线下面积（area under curve，AUC）为0.84（95% CI：0.780 ~ 0.899），灵敏度为85.0%，特异度为72.4%。在校准曲线中，预测结果与实际结果吻合良好，具有良好的预测精准度。DCA表明，肿瘤退缩预测模型可以为诊断带来临床净收益。

结论：

治疗前肿瘤直径、nCRT后距离手术的时间、D-二聚体、PNI、CEA及EMVI是LARC nCRT后肿瘤退缩的独立风险因素，基于上述因素构建的肿瘤退缩预测模型对LARC患者nCRT后的肿瘤退缩具有较好的预测效能。

Abstract

Background and purpose:

The standard therapy for locally advanced rectal cancer (LARC) is neoadjuvant chemoradiotherapy (nCRT) followed by surgery. NCRT can make the tumor regress and downstage

and increase the R0 resection rate. However

individual differences in rectal cancer are large

and some patients respond poorly to nCRT and cannot benefit from nCRT. Therefore

it is necessary to establish effective screening measures to identify patients

with poor response to nCRT. This study aimed to analyze the influencing factors of nCRT for LARC and construct the tumor regression prediction model.

Methods:

Data of 158 LARC patients who underwent total mesenteric resection after receiving nCRT at the First Hospital Affiliated to Air Force Medical University from January 2016 to December 2020 were collected. Baseline clinical indicators before nCRT were collected

including laboratory examination

tumor markers and magnetic resonance imaging (MRI). According to the tumor size reported by MRI before and after nCRT

Response Evaluation Criteria in Solid Tumors (RECIST) was used to evaluate the extent of tumor regression after nCRT. After receiver operating characteristic (ROC) curve was used to standardize the clinical baseline indicators

logistic regression analysis was carried out to screen the factors affecting the tumor regression. The tumor regression prediction model was constructed by logistic regression

and the performance of the model was evaluated based on decision curve analysis (DCA) and the calibration curve. The accuracy of the model was tested by 10-fold cross-validation.

Results:

This retrospective cohort study enrolled 158 patients

in which

98 patients achieved complete response (CR) or partial response (PR). The objective response rate was 62%. Sixty patients had poor response to nCRT

either stable disease (SD) or progressive disease (PD). Multivariate logistic regression analysis showed that tumor diameter before treatment (

0.001)

time to surgery after nCRT (

= 0.006)

D-dimer (

= 0.010)

prognostic nutrition index (PNI) (

= 0.035)

carcinoembryonic antigen (CEA) (

= 0.004) and extramural vascular invasion (EMVI) (

= 0.026) were significantly related to tumor regression after nCRT. The area under ROC curve (AUC) of tumor regression after nCRT prediction model for LARC was 0.84 (95% CI: 0.780-0.899)

sen

sitivity was 85.0%

and specificity was 72.4%. In the calibration curve

the predicted results were in good agreement with the actual results

and the prediction accuracy was good. The DCA showed that the tumor regression prediction model could bring clinical net benefit to diagnosis.

Conclusion:

Tumor diameter before treatment

time to surgery after nCRT

D-dimer

PNI

CEA and EMVI are independent risk factors for the tumor regression after nCRT in LARC patients. The tumor regression prediction model based on the above factors has good predictive efficacy for the tumor regression after nCRT in LARC patients.

关键词

Keywords

references

SUNG H , FERLAY J , SIEGEL R L , et al . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin , 2021 , 71 ( 3 ): 209 - 249 . DOI: 10.3322/caac.v71.3 http://doi.org/10.3322/caac.v71.3 https://acsjournals.onlinelibrary.wiley.com/toc/15424863/71/3 https://acsjournals.onlinelibrary.wiley.com/toc/15424863/71/3

National Health Commission of the People’s Republic of China, Chinese Society of Oncology . Chinese protocol of diagnosis and treatment of colorectal cancer (2023 edition) [J ] . Chin J Surg , 2023 , 61 ( 8 ): 617 - 644 .

KENNEDY A , COHN M , COLDWELL D M , et al . Erratum to updated survival outcomes and analysis of long-term survivors from the MORE study on safety and efficacy of radioembolization in patients with unresectable colorectal cancer liver metastases [J ] . J Gastrointest Oncol , 2018 , 9 ( 2 ): E13 -E14. DOI: 10.21037/jgo http://doi.org/10.21037/jgo http://jgo.amegroups.com/ http://jgo.amegroups.com/

BENSON A B , VENOOK A P , AL-HAWARY M M , et al . Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology [J ] . J Natl Compr Canc Netw , 2022 , 20 ( 10 ): 1139 - 1167 . DOI: 10.6004/jnccn.2022.0051 http://doi.org/10.6004/jnccn.2022.0051 https://jnccn.org/view/journals/jnccn/20/10/article-p1139.xml https://jnccn.org/view/journals/jnccn/20/10/article-p1139.xml

GÉRARD J P , CONROY T , BONNETAIN F , et al . Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T 3-4 rectal cancers: results of FFCD 9203 [J ] . J Clin Oncol , 2006 , 24 ( 28 ): 4620 - 4625 . DOI: 10.1200/JCO.2006.06.7629 http://doi.org/10.1200/JCO.2006.06.7629 https://ascopubs.org/doi/10.1200/JCO.2006.06.7629 https://ascopubs.org/doi/10.1200/JCO.2006.06.7629

BOSSET J F , COLLETTE L , CALAIS G , et al . Chemotherapy with preoperative radiotherapy in rectal cancer [J ] . N Engl J Med , 2006 , 355 ( 11 ): 1114 - 1123 . DOI: 10.1056/NEJMoa060829 http://doi.org/10.1056/NEJMoa060829 http://www.nejm.org/doi/abs/10.1056/NEJMoa060829 http://www.nejm.org/doi/abs/10.1056/NEJMoa060829

MAAS M , NELEMANS P J , VALENTINI V , et al . Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data [J ] . Lancet Oncol , 2010 , 11 ( 9 ): 835 - 844 . DOI: 10.1016/S1470-2045(10)70172-8 http://doi.org/10.1016/S1470-2045(10)70172-8

AGARWAL A , CHANG G J , HU C Y , et al . Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy [J ] . Cancer , 2013 , 119 ( 24 ): 4231 - 4241 . DOI: 10.1002/cncr.28331 http://doi.org/10.1002/cncr.28331

MCCOY M J , HEMMINGS C , ANYAEGBU C C , et al . Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment response [J ] . Oncotarget , 2017 , 8 ( 12 ): 19803 - 19813 . DOI: 10.18632/oncotarget.15048 http://doi.org/10.18632/oncotarget.15048

YI Y X , SHEN L J , SHI W , et al . Gut microbiome components predict response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a prospective, longitudinal study [J ] . Clin Cancer Res , 2021 , 27 ( 5 ): 1329 - 1340 . DOI: 10.1158/1078-0432.CCR-20-3445 http://doi.org/10.1158/1078-0432.CCR-20-3445

EISENHAUER E A , THERASSE P , BOGAERTS J , et al . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) [J ] . Eur J Cancer , 2009 , 45 ( 2 ): 228 - 247 . DOI: 10.1016/j.ejca.2008.10.026 http://doi.org/10.1016/j.ejca.2008.10.026

PARK I J , YOU Y N , AGARWAL A , et al . Neoadjuvant treatment response as an early response indicator for patients with rectal cancer [J ] . J Clin Oncol , 2012 , 30 ( 15 ): 1770 - 1776 . DOI: 10.1200/JCO.2011.39.7901 http://doi.org/10.1200/JCO.2011.39.7901

ZENG W G , LIANG J W , WANG Z , et al . Clinical parameters predicting pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer [J ] . Chin J Cancer , 2015 , 34 ( 10 ): 468 - 474 .

BUGG W G , ANDREOU A K , BISWAS D , et al . The prognostic significance of MRI-detected extramural venous invasion in rectal carcinoma [J ] . Clin Radiol , 2014 , 69 ( 6 ): 619 - 623 . DOI: 10.1016/j.crad.2014.01.010 http://doi.org/10.1016/j.crad.2014.01.010

MCCAWLEY N , CLANCY C , O’NEILL B D , et al . Mucinous rectal adenocarcinoma is associated with a poor response to neoadjuvant chemoradiotherapy: a systematic review and meta-analysis [J ] . Dis Colon Rectum , 2016 , 59 ( 12 ): 1200 - 1208 .

SONG M , LI S , WANG H Z , et al . MRI radiomics independent of clinical baseline characteristics and neoadjuvant treatment modalities predicts response to neoadjuvant therapy in rectal cancer [J ] . Br J Cancer , 2022 , 127 ( 2 ): 249 - 257 . DOI: 10.1038/s41416-022-01786-7 http://doi.org/10.1038/s41416-022-01786-7

FENG L L , LIU Z Y , LI C F , et al . Development and validation of a radiopathomics model to predict pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a multicentre observational study [J ] . Lancet Digit Health , 2022 , 4 ( 1 ): e8 - e17 .

BEDRIKOVETSKI S , TRAEGER L , VATHER R , et al . Clinical and biochemical predictors of tumor response after neoadjuvant therapy in rectal cancer [J ] . Asia Pac J Clin Oncol , 2023 , 19 ( 3 ): 365 - 373 . DOI: 10.1111/ajco.v19.3 http://doi.org/10.1111/ajco.v19.3 https://onlinelibrary.wiley.com/toc/17437563/19/3 https://onlinelibrary.wiley.com/toc/17437563/19/3

GAMBACORTA M A , MASCIOCCHI C , CHILOIRO G , et al . Timing to achieve the highest rate of pCR after preoperative radiochemotherapy in rectal cancer: a pooled analysis of 3085 patients from 7 randomized trials [J ] . Radiother Oncol , 2021 , 154 : 154 - 160 . DOI: 10.1016/j.radonc.2020.09.026 http://doi.org/10.1016/j.radonc.2020.09.026

HUANG W H , WANG S G , ZHANG H , et al . Prognostic significance of combined fibrinogen concentration and neutrophil-to-lymphocyte ratio in patients with resectable non-small cell lung cancer [J ] . Cancer Biol Med , 2018 , 15 ( 1 ): 88 - 96 . DOI: 10.20892/j.issn.2095-3941.2017.0124 http://doi.org/10.20892/j.issn.2095-3941.2017.0124

BEER J H , HAEBERLI A , VOGT A , et al . Coagulation markers predict survival in cancer patients [J ] . Thromb Haemost , 2002 , 88 ( 5 ): 745 - 749 . DOI: 10.1055/s-0037-1613296 http://doi.org/10.1055/s-0037-1613296 http://www.thieme-connect.de/DOI/DOI?10.1055/s-0037-1613296 http://www.thieme-connect.de/DOI/DOI?10.1055/s-0037-1613296

SHIBUTANI M , KASHIWAGI S , FUKUOKA T , et al . The significance of the D-dimer level as a prognostic marker for survival and treatment outcomes in patients with stage Ⅳ colorectal cancer [J ] . In Vivo , 2023 , 37 ( 1 ): 440 - 444 . DOI: 10.21873/invivo.13097 http://doi.org/10.21873/invivo.13097 http://iv.iiarjournals.org/lookup/doi/10.21873/invivo.13097 http://iv.iiarjournals.org/lookup/doi/10.21873/invivo.13097

MUSCARITOLI M , ARENDS J , BACHMANN P , et al . ESPEN practical guideline: clinical nutrition in cancer [J ] . Clin Nutr , 2021 , 40 ( 5 ): 2898 - 2913 . DOI: 10.1016/j.clnu.2021.02.005 http://doi.org/10.1016/j.clnu.2021.02.005

XIE H L , WEI L S , YUAN G H , et al . Prognostic value of prognostic nutritional index in patients with colorectal cancer undergoing surgical treatment [J ] . Front Nutr , 2022 , 9 : 794489 . DOI: 10.3389/fnut.2022.794489 http://doi.org/10.3389/fnut.2022.794489 https://www.frontiersin.org/articles/10.3389/fnut.2022.794489/full https://www.frontiersin.org/articles/10.3389/fnut.2022.794489/full

HU H B , KANG L , ZHANG J W , et al . Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial [J ] . Lancet Gastroenterol Hepatol , 2022 , 7 ( 1 ): 38 - 48 .

SAUER R , BECKER H , HOHENBERGER W , et al . Preoperative versus postoperative chemoradiotherapy for rectal cancer [J ] . N Engl J Med , 2004 , 351 ( 17 ): 1731 - 1740 . DOI: 10.1056/NEJMoa040694 http://doi.org/10.1056/NEJMoa040694 http://www.nejm.org/doi/abs/10.1056/NEJMoa040694 http://www.nejm.org/doi/abs/10.1056/NEJMoa040694

MOMMA T , OKAYAMA H , KANKE Y , et al . Validation of gene expression-based predictive biomarkers for response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer [J ] . Cancers (Basel) , 2021 , 13 ( 18 ): 4642 . DOI: 10.3390/cancers13184642 http://doi.org/10.3390/cancers13184642 https://www.mdpi.com/2072-6694/13/18/4642 https://www.mdpi.com/2072-6694/13/18/4642

GARCIA-AGUILAR J , CHOW O S , SMITH D D , et al . Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial [J ] . Lancet Oncol , 2015 , 16 ( 8 ): 957 - 966 . DOI: 10.1016/S1470-2045(15)00004-2 http://doi.org/10.1016/S1470-2045(15)00004-2 https://linkinghub.elsevier.com/retrieve/pii/S1470204515000042 https://linkinghub.elsevier.com/retrieve/pii/S1470204515000042

CERCEK A , ROXBURGH C S D , STROMBOM P , et al . Adoption of total neoadjuvant therapy for locally advanced rectal cancer [J ] . JAMA Oncol , 2018 , 4 ( 6 ): e180071 . DOI: 10.1001/jamaoncol.2018.0071 http://doi.org/10.1001/jamaoncol.2018.0071 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2018.0071 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2018.0071

浏览量

1996

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

新辅助放化疗-直肠前切除手术后重建直肠狭窄的临床危险因素分析

体素内不相干运动扩散加权成像在预测局部进展期直肠癌新辅助放化疗疗效中的初步研究

机体组分在直肠癌患者术后长期预后预测中的价值及模型建立

直肠癌外科治疗的创新模式探讨

直肠癌患者经肛门或腹腔镜行全直肠系膜切除术后的生活质量分析：一项回顾性队列研究